# EDGAR Filing Document

**Accession Number:** 0001039399
**File Stem:** 0001039399-25-000113
**Filing Date:** 2025-11
**Character Count:** 140918
**Document Hash:** f299863cc840063d5ebae008baaf9a94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001039399-25-000113.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001039399-25-000113

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 83

**CONFORMED PERIOD OF REPORT**: 20250927

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FORMFACTOR INC
- **CENTRAL INDEX KEY:** 0001039399
- **STANDARD INDUSTRIAL CLASSIFICATION:** SEMICONDUCTORS & RELATED DEVICES [3674]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 133711155
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1227

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50307
- **FILM NUMBER:** 251448861

**BUSINESS ADDRESS:**
- **STREET 1:** 7005 SOUTHFRONT ROAD
- **CITY:** LIVERMORE
- **STATE:** CA
- **ZIP:** 94551
- **BUSINESS PHONE:** 9252904000

**MAIL ADDRESS:**
- **STREET 1:** 7005 SOUTHFRONT ROAD
- **CITY:** LIVERMORE
- **STATE:** CA
- **ZIP:** 94551

?xml version='1.0' encoding='ASCII'? form-20250927

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q** 

**(Mark one)**

**☒&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 27, 2025** 

**Or** 

**☐&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission file number: 000-50307** 

**FormFactor, Inc.** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **13-3711155** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**7005 Southfront Road, Livermore, California 94551** 

(Address of principal executive offices, including zip code)

**(925) 290-4000** 

(Registrant's telephone number, including area code)

Securities registered pursuant to Section12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common stock, $0.001 par value** | **FORM** | **Nasdaq Global Select Market** |

---

______________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of the Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large Accelerated Filer | ☒ | Accelerated Filer | ☐ | Non-accelerated Filer | ☐ |
| Smaller Reporting Company | ☐ | Emerging Growth Company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No ☒

As of October 29, 2025, 77,517,097 shares of the registrant's common stock, par value $0.001 per share, were outstanding.

------

**FORMFACTOR, INC.**

**FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 27, 2025**

**INDEX**

---

| | | |
|:---|:---|:---|
| **<u>[Part I.](#ic8327f5e8d884817aa4f6874d779607f_10)</u>** | **<u>[Financial Information](#ic8327f5e8d884817aa4f6874d779607f_10)</u>** | |
| <u>[Item 1.](#ic8327f5e8d884817aa4f6874d779607f_13)</u> | <u>[Financial Statements (Unaudited):](#ic8327f5e8d884817aa4f6874d779607f_10)</u> | |
| | &nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets as of](#ic8327f5e8d884817aa4f6874d779607f_16)September 27, 2025[and](#ic8327f5e8d884817aa4f6874d779607f_16)December 28, 2024</u> | <u>[3](#ic8327f5e8d884817aa4f6874d779607f_16)</u> |
| | &nbsp;&nbsp;<u>[Condensed Consolidated Statements of Incom](#ic8327f5e8d884817aa4f6874d779607f_19)[e fo](#ic8327f5e8d884817aa4f6874d779607f_19)[r the](#ic8327f5e8d884817aa4f6874d779607f_19)three and nine[mo](#ic8327f5e8d884817aa4f6874d779607f_19)[nths ended](#ic8327f5e8d884817aa4f6874d779607f_19)September 27, 2025[and](#ic8327f5e8d884817aa4f6874d779607f_19)September 28, 2024</u> | <u>[4](#ic8327f5e8d884817aa4f6874d779607f_19)</u> |
| | &nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income for the](#ic8327f5e8d884817aa4f6874d779607f_22)three and nine[months ended](#ic8327f5e8d884817aa4f6874d779607f_22)September 27, 2025[and](#ic8327f5e8d884817aa4f6874d779607f_22)September 28, 2024</u> | <u>[5](#ic8327f5e8d884817aa4f6874d779607f_22)</u> |
| | &nbsp;&nbsp;<u>[Condensed Consolidated Statement of Stockholders' Equity for the](#ic8327f5e8d884817aa4f6874d779607f_25)three and nine[months ended](#ic8327f5e8d884817aa4f6874d779607f_25)September 27, 2025[and](#ic8327f5e8d884817aa4f6874d779607f_25)September 28, 2024</u> | <u>[6](#ic8327f5e8d884817aa4f6874d779607f_25)</u> |
|  | &nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows for the](#ic8327f5e8d884817aa4f6874d779607f_28)nine[months ended](#ic8327f5e8d884817aa4f6874d779607f_28)September 27, 2025[and](#ic8327f5e8d884817aa4f6874d779607f_28)September 28, 2024</u> | <u>[8](#ic8327f5e8d884817aa4f6874d779607f_28)</u> |
| | &nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#ic8327f5e8d884817aa4f6874d779607f_31)</u> | <u>[10](#ic8327f5e8d884817aa4f6874d779607f_31)</u> |
| <u>[Item 2.](#ic8327f5e8d884817aa4f6874d779607f_97)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ic8327f5e8d884817aa4f6874d779607f_97)</u> | <u>[24](#ic8327f5e8d884817aa4f6874d779607f_97)</u> |
| <u>[Item 3.](#ic8327f5e8d884817aa4f6874d779607f_121)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ic8327f5e8d884817aa4f6874d779607f_121)</u> | <u>[34](#ic8327f5e8d884817aa4f6874d779607f_121)</u> |
| <u>[Item 4.](#ic8327f5e8d884817aa4f6874d779607f_124)</u> | <u>[Controls and Procedures](#ic8327f5e8d884817aa4f6874d779607f_124)</u> | <u>[35](#ic8327f5e8d884817aa4f6874d779607f_124)</u> |
| **<u>[Part II.](#ic8327f5e8d884817aa4f6874d779607f_127)</u>** | **<u>[Other Information](#ic8327f5e8d884817aa4f6874d779607f_127)</u>** | <u>[35](#ic8327f5e8d884817aa4f6874d779607f_127)</u> |
| <u>[Item 1A.](#ic8327f5e8d884817aa4f6874d779607f_130)</u> | <u>[Risk Factors](#ic8327f5e8d884817aa4f6874d779607f_130)</u> | <u>[35](#ic8327f5e8d884817aa4f6874d779607f_130)</u> |
| <u>[Item 2.](#ic8327f5e8d884817aa4f6874d779607f_133)</u> | <u>[Unregistered Sales of Equity Securities and use of proceeds](#ic8327f5e8d884817aa4f6874d779607f_133)</u> | <u>[36](#ic8327f5e8d884817aa4f6874d779607f_133)</u> |
| <u>Item 5.</u> | <u>Other Information</u> | <u>[36](#ic8327f5e8d884817aa4f6874d779607f_136)</u> |
| <u>[Item 6.](#ic8327f5e8d884817aa4f6874d779607f_139)</u> | <u>[Exhibits](#ic8327f5e8d884817aa4f6874d779607f_139)</u> | <u>[37](#ic8327f5e8d884817aa4f6874d779607f_139)</u> |
| <u>[Signatures](#ic8327f5e8d884817aa4f6874d779607f_142)</u> | | <u>[38](#ic8327f5e8d884817aa4f6874d779607f_142)</u> |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. *Financial Statements***

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands, except share and per share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **September 27,<br>2025** | **December 28,<br>2024** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $97678 | $190728 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 168351 | 169295 |
| &nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $121 and $4 | 133316 | 104294 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 108830 | 101676 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 1058 | 3746 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 50027 | 35389 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 559260 | 605128 |
| Restricted cash | 2375 | 2732 |
| Operating lease, right-of-use-assets | 17471 | 22579 |
| Property, plant and equipment, net of accumulated depreciation | 257912 | 210230 |
| Equity investment | 66441 |  |
| Goodwill | 200841 | 199171 |
| Intangibles, net | 8385 | 10355 |
| Deferred tax assets | 88265 | 92012 |
| Other assets | 2042 | 4008 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1202992 | $1146215 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $58389 | $62287 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities | 41574 | 43742 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt, net of unamortized issuance costs | 1129 | 1106 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 21623 | 15847 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | 7400 | 8363 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 130115 | 131345 |
| Long-term debt, less current portion, net of unamortized issuance costs | 11359 | 12208 |
| Long-term operating lease liabilities | 13317 | 17550 |
| Deferred grant | 18000 | 18000 |
| Other liabilities | 20586 | 19344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 193377 | 198447 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;Common stock, $0.001 par value: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250,000,000 shares authorized; 77,517,097 and 77,114,633 shares issued and outstanding | 78 | 77 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 857401 | 837586 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 48 | (10840) |
| &nbsp;&nbsp;&nbsp;Accumulated income | 152088 | 120945 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1009615 | 947768 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1202992 | $1146215 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

**(In thousands, except per share amounts)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Revenues | $202676 | $207917 | $569830 | $574116 |
| Cost of revenues | 122050 | 123212 | 351743 | 339773 |
| Gross profit | 80626 | 84705 | 218087 | 234343 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | 28686 | 31243 | 85279 | 91434 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 32971 | 35607 | 97907 | 106560 |
| &nbsp;&nbsp;&nbsp;Factory start-up costs | 964 |  | 1321 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 62621 | 66850 | 184507 | 197994 |
| Gain on sale of business |  |  |  | 20581 |
| Operating income | 18005 | 17855 | 33580 | 56930 |
| Interest income, net | 1976 | 3650 | 7935 | 10221 |
| Other income (expense), net | 444 | (558) | 1328 | 322 |
| Income before income taxes and equity investment | 20425 | 20947 | 42843 | 67473 |
| Provision for income taxes | 5937 | 2211 | 9384 | 7564 |
| Loss (income) from equity investment | (1168) |  | 2316 |  |
| Net income | $15656 | $18736 | $31143 | $59909 |
| Net income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $0.20 | $0.24 | $0.40 | $0.77 |
| &nbsp;&nbsp;&nbsp;Diluted | $0.20 | $0.24 | $0.40 | $0.76 |
| Weighted-average number of shares used in per share calculations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 77387 | 77406 | 77270 | 77364 |
| &nbsp;&nbsp;&nbsp;Diluted | 77734 | 78439 | 77684 | 78495 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(In thousands)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Net income | $15656 | $18736 | $31143 | $59909 |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (2621) | 4326 | 9081 | 968 |
| &nbsp;&nbsp;&nbsp;Unrealized gains on available-for-sale marketable securities | 114 | 1669 | 374 | 1432 |
| &nbsp;&nbsp;&nbsp;Unrealized gains (losses) on derivative instruments | (895) | 180 | 1433 | (121) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax: | (3402) | 6175 | 10888 | 2279 |
| Comprehensive income | $12254 | $24911 | $42031 | $62188 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(In thousands, except shares)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Shares of<br>Common<br>Stock** | **Common<br>Stock** | **Additional<br>Paid-in<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br> Income (Loss)** | **Accumulated**<br>**Income** | **Total** |
| | **Three Months Ended September 27, 2025** | **Three Months Ended September 27, 2025** | **Three Months Ended September 27, 2025** | **Three Months Ended September 27, 2025** | **Three Months Ended September 27, 2025** | **Three Months Ended September 27, 2025** |
| **Balances, June 28, 2025** | 77111430 | $77 | $850064 | $3450 | $136432 | $990023 |
| Issuance of common stock under the Employee Stock Purchase Plan | 188138 |  | 4543 |  |  | 4543 |
| Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 277529 | 1 | (4991) |  |  | (4990) |
| Purchase and retirement of common stock through repurchase program | (60000) |  | (1559) |  |  | (1559) |
| Stock-based compensation |  |  | 9344 |  |  | 9344 |
| Other comprehensive loss |  |  |  | (3402) |  | (3402) |
| Net income |  |  |  |  | 15656 | 15656 |
| **Balances, September 27, 2025** | 77517097 | $78 | $857401 | $48 | $152088 | $1009615 |
|  | **Nine Months Ended September 27, 2025** | **Nine Months Ended September 27, 2025** | **Nine Months Ended September 27, 2025** | **Nine Months Ended September 27, 2025** | **Nine Months Ended September 27, 2025** | **Nine Months Ended September 27, 2025** |
| **Balances, December 28, 2024** | 77114633 | $77 | $837586 | $(10840) | $120945 | $947768 |
| Issuance of common stock under the Employee Stock Purchase Plan | 385189 |  | 11119 |  |  | 11119 |
| Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 482304 | 1 | (8610) |  |  | (8609) |
| Issuance of common stock pursuant to private placement | 334971 |  | 15000 |  |  | 15000 |
| Purchase and retirement of common stock through repurchase program | (800000) |  | (26168) |  |  | (26168) |
| Stock-based compensation |  |  | 28474 |  |  | 28474 |
| Other comprehensive income |  |  |  | 10888 |  | 10888 |
| Net income |  |  |  |  | 31143 | 31143 |
| **Balances, September 27, 2025** | 77517097 | $78 | $857401 | $48 | $152088 | $1009615 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (continued)**

**(In thousands, except shares)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Shares of<br>Common<br>Stock** | **Common<br>Stock** | **Additional<br>Paid-in<br>Capital** | **Accumulated**<br>**Other**<br>**Comprehensive**<br> **Loss** | **Accumulated**<br>**Income** | **Total** |
| | **Three Months Ended September 28, 2024** | **Three Months Ended September 28, 2024** | **Three Months Ended September 28, 2024** | **Three Months Ended September 28, 2024** | **Three Months Ended September 28, 2024** | **Three Months Ended September 28, 2024** |
| **Balances, June 29, 2024** | 77281052 | $77 | $863283 | $(7948) | $92504 | $947916 |
| Issuance of common stock under the Employee Stock Purchase Plan | 143975 |  | 4800 |  |  | 4800 |
| Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 428694 |  | (14421) |  |  | (14421) |
| Purchase and retirement of common stock through repurchase program | (405732) |  | (16909) |  |  | (16909) |
| Stock-based compensation |  |  | 8713 |  |  | 8713 |
| Other comprehensive income |  |  |  | 6175 |  | 6175 |
| Net income |  |  |  |  | 18736 | 18736 |
| **Balances, September 28, 2024** | 77447989 | $77 | $845466 | $(1773) | $111240 | $955010 |
|  | **Nine Months Ended September 28, 2024** | **Nine Months Ended September 28, 2024** | **Nine Months Ended September 28, 2024** | **Nine Months Ended September 28, 2024** | **Nine Months Ended September 28, 2024** | **Nine Months Ended September 28, 2024** |
| **Balances, December 30, 2023** | 77376903 | $77 | $861448 | $(4052) | $51331 | $908804 |
| Issuance of common stock under the Employee Stock Purchase Plan | 340989 |  | 9748 |  |  | 9748 |
| Issuance of common stock pursuant to vesting of restricted stock units, net of stock withheld for tax | 619780 |  | (17990) |  |  | (17990) |
| Purchase and retirement of common stock through repurchase program | (889683) |  | (37211) |  |  | (37211) |
| Stock-based compensation |  |  | 29471 |  |  | 29471 |
| Other comprehensive income |  |  |  | 2279 |  | 2279 |
| Net income |  |  |  |  | 59909 | 59909 |
| **Balances, September 28, 2024** | 77447989 | $77 | $845466 | $(1773) | $111240 | $955010 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** |
| **Cash flows from operating activities:** | | |
| &nbsp;&nbsp;&nbsp;Net income | $31143 | $59909 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 28161 | 24117 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction in the carrying amount of right-of-use assets | 5228 | 5129 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 28703 | 29550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax benefit | 3851 | (14044) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for excess and obsolete inventories | 9922 | 10052 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash restructuring charges | 2119 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of business and assets | (103) | (20581) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss from equity investment | 2316 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments to reconcile net income to net cash provided by operating activities | (771) | (2178) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (28072) | (13300) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (13912) | (7573) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (4527) | (256) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (69) | 295 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 5699 | (8780) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (996) | 7368 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 596 | 9331 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenues | 6188 | 7883 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (6053) | (5301) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 69423 | 81621 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition of property, plant and equipment | (92345) | (30773) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of business and assets | 103 | 21585 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of equity investment | (67156) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | (95378) | (109727) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of promissory note receivable |  | (1500) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturities and sales of marketable securities | 98281 | 94263 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (156495) | (26152) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuances of common stock | 26119 | 9748 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of common stock through stock repurchase program, including excise tax paid | (26244) | (37211) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax withholdings related to net share settlements of equity awards | (8609) | (17990) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments on term loan | (826) | (803) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (9560) | (46256) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 537 | 3 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (96095) | 9216 |
| Cash, cash equivalents and restricted cash, beginning of year | 197206 | 181273 |
| Cash, cash equivalents and restricted cash, end of period | $101111 | $190489 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** |
| **Non-cash investing and financing activities:** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease in accounts payable and accrued liabilities related to property, plant and equipment purchases | $10655 | $2915 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease, right-of-use assets obtained in exchange for lease obligations | 448 |  |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes, net | $7614 | $13114 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | 276 | 298 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating cash outflows from operating leases | 7314 | 6960 |
| **Reconciliation of cash, cash equivalents and restricted cash:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $97678 | $184506 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash, current | 1058 | 3773 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 2375 | 2210 |
| **Total cash, cash equivalents and restricted cash** | $101111 | $190489 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

**FORMFACTOR, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**Note 1 — Basis of Presentation and Significant Accounting Policies**

**Basis of Presentation**

The accompanying condensed consolidated financial information of FormFactor, Inc. is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods. The condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2024 Annual Report on Form 10-K filed with the SEC on February 21, 2025. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.

**Fiscal Year** 

We operate on a 52/53 week fiscal year, whereby the fiscal year ends on the last Saturday of December. Fiscal 2025 and 2024 each contain 52 weeks and the nine months ended September 27, 2025 and September 28, 2024 each contained 39 weeks. Fiscal 2025 will end on December 27, 2025.

**Significant Accounting Policies**

Our significant accounting policies have not changed during the nine months ended September 27, 2025 from those disclosed in our Annual Report on Form 10-K for the year ended December 28, 2024, except for:

*Equity Investment*

On February 21, 2025, Frontier Investments Co., Ltd ("HoldCo"), a joint holding company in which we hold a 20% share of the equity and an affiliate of MBK Partners holds an 80% share of the equity, through HoldCo's wholly-owned subsidiary, FM Holdings Co., Ltd., acquired 100% of the shares of FICT Limited ("FICT") from Advantage Partners Inc. Our initial $67.2 million investment comprised of the funding of our share of the purchase price of $59.6 million, subject to changes in foreign currency fluctuations, and acquisition costs of $7.5 million. Headquartered in Nagano, Japan, FICT is a provider of semiconductor test and high-performance computing industries with complex multi-layer organic substrates, printed circuit boards, and related leading-edge technologies and services.

This investment is accounted for as an equity method investment, with the income or loss from our pro-rata share of the HoldCo's financial results changing our carrying value of the investment. We report our pro-rata share of the HoldCo's financial results on a one-quarter lag as their results are not available in time to be recorded in the concurrent period. During the three and nine months ended September 27, 2025, we recorded income of $1.2 million and a loss of $2.3 million, respectively, from our equity share of the HoldCo using lag reporting. As of September 27, 2025, the carrying value of our investment was $66.4 million, and recorded in Equity investment on our Condensed Consolidated Balance Sheets.

As of September 27, 2025, we had a $7.3 million basis difference between the carrying value of our investment and our proportionate share of the underlying net assets of the Holdco. The basis difference is accounted for as equity method goodwill that is not amortized.

We engage in transactions with FICT, a related party and a supplier, in the normal course of business and at arm's length. Total related party purchases of inventory from FICT during the three and nine months ended September 27, 2025 was $2.6 million and $7.4 million, respectively.

**New Accounting Pronouncements**

*ASU 2024-03*

In November 2024, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2024-03, "*Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*." This ASU requires an entity to disclose, in tabular format, in the notes to the financial statements, specific information about certain costs and expenses. Although the ASU does not change the expense captions an entity presents on the face of the income statement, it requires disaggregation of certain expense captions into specified categories. The amendments in the ASU are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted. An entity may apply the amendments prospectively for reporting periods after the effective date or retrospectively to any or all prior periods presented in

------

the financial statements. This ASU will impact only our disclosures and not our financial condition and results of operations. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.

*ASU 2023-09*

In December 2023, the FASB issued ASU 2023-09, "*Income Taxes (Topic 740): Improvements to Income Tax Disclosures.*" The ASU includes requirements that an entity disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are greater than five percent of the amount computed by multiplying pretax income by the applicable statutory income tax rate. The standard also requires that entities disclose income before income taxes and provision for income taxes disaggregated between domestic and foreign. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. An entity may apply the amendments outlined in this ASU prospectively by providing the revised disclosures for the current period and continuing to provide the pre-ASU disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all periods presented. We will adopt this ASU retrospectively for the period ending December 27, 2025, and it will impact only our disclosures with no impacts to our financial condition and results of operations.

**Reclassifications**

Certain immaterial reclassifications were made to the prior year financial statements to conform to the current year presentation. In the current period we combined depreciation and amortization into a single line on the Condensed Consolidated Statement of Cash Flows.

**Note 2 — Concentration of Credit and Other Risks**

Each of the following customers accounted for 10% or more of our revenues for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| SK hynix Inc. | 24.5% | 18.1% | 24.3% | 17.8% |
| Intel Corporation | \* | 17.1% | 11.2% | 16.6% |
|  | 24.5% | 35.2% | 35.5% | 34.4% |

---

\* Less than 10% of revenues.

At September 27, 2025, two customers accounted for 21.5% and 17.6% of gross accounts receivable, and at December 28, 2024, one customer accounted for 22.0% of gross accounts receivable.

**Note 3 — Inventories, net** 

Inventories are stated at the lower of cost (principally standard cost, which approximates actual cost on a first in, first out basis) or net realizable value.

Inventories, net, consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 27,<br>2025** | **December 28,<br>2024** |
| Raw materials | $46655 | $45547 |
| Work-in-progress | 42912 | 38366 |
| Finished goods | 19263 | 17763 |
|  | $108830 | $101676 |

---

**Note 4 — Divestiture**

On February 26, 2024, we closed on the sale of operations in China to Grand Junction and received total consideration of $21.4 million, net of cash transferred and transaction expenses, and after customary adjustments for indebtedness and changes in net working capital. The disposition of the China operations did not meet the criteria to be classified as a discontinued operation in our financial statements because the disposition did not represent a strategic shift that had, or will have, a major effect on our operations and financial results.

------

The following table summarizes the fair value of the sale proceeds received in connection with the divestiture (in thousands):

---

| | |
|:---|:---|
| | **February 26, 2024** |
| Gross purchase price | $25000 |
| Working capital adjustment | 159 |
| Cash transferred to the buyer at closing | (2743) |
| Direct costs to sell | (986) |
| &nbsp;&nbsp;Fair value of sale consideration, net | $21430 |

---

The carrying amount of net assets associated with the China operations was approximately $1.2 million. The major classes of assets and liabilities sold consisted of the following (in thousands):

---

| | |
|:---|:---|
| | **February 26, 2024** |
| **ASSETS** | |
| Accounts receivable, net | $1174 |
| Inventories, net | 3729 |
| Other current assets | 391 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 5294 |
| Property, plant and equipment, net | 1283 |
| Goodwill | 1117 |
| Other assets | 3029 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $10723 |
| **LIABILITIES** |  |
| Deferred revenue | $3739 |
| Other current liabilities | 1546 |
| Other liabilities | 4283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $9568 |

---

As a result of the divestiture, we recognized a pre-tax gain of $20.3 million. We recorded income tax expense associated with the divestiture of approximately $3.3 million.

**Note 5 — Goodwill and Intangible Assets** 

Goodwill by reportable segment was as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| | **Probe Cards** | **Systems** | **Total** |
| **Goodwill, as of December 30, 2023** | $178424 | $22666 | $201090 |
| &nbsp;&nbsp;Reduction - China divestiture | (1055) | (62) | (1117) |
| &nbsp;&nbsp;Foreign currency translation |  | (802) | (802) |
| **Goodwill, as of December 28, 2024** | 177369 | 21802 | 199171 |
| &nbsp;&nbsp;Foreign currency translation |  | 1670 | 1670 |
| **Goodwill, as of September 27, 2025** | $177369 | $23472 | $200841 |

---

We have not recorded goodwill impairments for the nine months ended September 27, 2025.

------

Intangible assets were as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **December 28, 2024** | **December 28, 2024** | **December 28, 2024** |
|<br>**Intangible Assets** | **Gross** | **Accumulated<br>Amortization** | **Net** | **Gross** | **Accumulated<br>Amortization** | **Net** |
| Existing developed technologies | $160680 | $152347 | $8333 | $159360 | $149631 | $9729 |
| Trade name | 7886 | 7883 | 3 | 7736 | 7700 | 36 |
| Customer relationships | 48227 | 48178 | 49 | 47831 | 47241 | 590 |
|  | $216793 | $208408 | $8385 | $214927 | $204572 | $10355 |

---

Amortization expense was included in our Condensed Consolidated Statements of Income as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Cost of revenues | $441 | $449 | $1398 | $1347 |
| Selling, general and administrative | 191 | 191 | 573 | 573 |
|  | $632 | $640 | $1971 | $1920 |

---

The estimated future amortization of definite-lived intangible assets, excluding in-process research and development, is as follows (in thousands):

---

| | |
|:---|:---|
| **Fiscal Year** | **Amount** |
| Remainder of 2025 | $493 |
| 2026 | 1763 |
| 2027 | 1741 |
| 2028 | 1630 |
| 2029 | 1630 |
| Thereafter | 1128 |
|  | $8385 |

---

**Note 6 — Accrued Liabilities**

Accrued liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 27,<br>2025** | **December 28,<br>2024** |
| Accrued compensation and benefits | $28984 | $26077 |
| Accrued warranty | 2543 | 3558 |
| Accrued income and other taxes | 2684 | 2969 |
| Accrued employee stock purchase plan contributions withheld | 2000 | 6034 |
| Other accrued expenses | 5363 | 5104 |
|  | $41574 | $43742 |

---

**Note 7 — Debt**

***Revolving Credit Agreement***

On July 29, 2025, we entered into a Revolving Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as Administrative Agent, and the lenders party thereto, providing us with a $150 million revolving credit facility (the "Facility"). The Facility has a maturity date of July 29, 2030. The Facility may be used for working capital and other general corporate purposes, subject to the terms and conditions set forth in the Credit Agreement. No amounts were outstanding under the Facility as of September 27, 2025.

Borrowings under the Facility will bear interest at a fluctuating rate per annum equal to, at our option, (i) the forward-looking secured overnight financing rate ("SOFR") term, (ii) a base rate set forth in the Credit Agreement, or (iii) a combination thereof, plus, in each case, an applicable margin calculated based on our leverage ratio. Voluntary prepayments are permissible without

------

penalty, subject to certain conditions pertaining to minimum notice and minimum prepayment and reduction amounts as described in the Credit Agreement.

The Facility also bears a quarterly commitment fee ranging from 0.15% to 0.25% on the daily amount by which the commitments under the Facility exceed the outstanding amount. The commitment fee as of September 27, 2025 was 0.15%.

The Credit Agreement contains customary representations and warranties, and affirmative and negative covenants and events of default, including limitations on subsidiary indebtedness and liens, and the requirement to maintain specified financial ratios including the requirement to maintain a consolidated total net leverage ratio not exceeding 3.50 to 1.00 as of the last day of each fiscal quarter with an increase to 4.00 to 1.00 for four quarters following a permitted acquisition.

***Building Term Loan and Interest Rate Swap***

On June 22, 2020, we entered into an $18.0 million 15-year credit facility loan agreement (the "Building Term Loan"). The proceeds of the Building Term Loan were used to purchase a building adjacent to our leased facilities in Livermore, California. On May 19, 2023, we amended the Building Term Loan, replacing the benchmark reference rate London Interbank Offered Rate ("LIBOR") with the term SOFR, with no change to the amount or timing of contractual cash flows.

The Building Term Loan bears interest at a rate equal to the applicable SOFR rate plus 1.86% per annum. Interest payments are payable in monthly installments over a fifteen-year period. The interest rate at September 27, 2025, before consideration of interest rate swap discussed in the next paragraph, was 6.14%. As of September 27, 2025, the balance outstanding pursuant to the Building Term Loan was $12.5 million.

On March 17, 2020, we entered into an interest rate swap agreement to hedge the interest payment on the Building Term Loan for the notional amount of $18.0 million, and an amortization period that matches the debt. As future levels of LIBOR over the life of the loan were uncertain, we entered into this interest-rate swap agreement to hedge the exposure in interest rate risks associated with movement in LIBOR rates. This agreement was amended on May 19, 2023 to replace the benchmark reference rate LIBOR with SOFR to match the Building Term Loan agreement (as amended). After the amendment, the interest rate swap continues to convert our floating-rate interest into a fixed-rate at 2.75%. As of September 27, 2025, the notional amount of the loan that is subject to this interest rate swap is $12.5 million.

**Note 8 — Fair Value and Derivative Instruments**

Whenever possible, the fair values of our financial assets and liabilities are determined using quoted market prices of identical securities or quoted market prices of similar securities from active markets. The three levels of inputs that may be used to measure fair value are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 valuations are obtained from real-time quotes for transactions in active exchange markets involving identical securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 valuations utilize significant observable inputs, such as quoted prices for similar assets or liabilities, quoted prices near the reporting date in markets that are less active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 valuations utilize unobservable inputs to the valuation methodology and include our own data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the nine months ended September 27, 2025 or the year ended December 28, 2024.

The carrying values of Cash, Accounts receivable, net, Restricted cash, Prepaid expenses and other current assets, Accounts payable, and Accrued liabilities approximate fair value due to their short maturities.

No changes were made to our valuation techniques during the first nine months of fiscal 2025.

------

***Assets and Liabilities Measured at Fair Value on a Recurring Basis***

Assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **September 27, 2025** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $41239 | $— | $— | $41239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 2534 |  | 2534 |
|  | 41239 | 2534 |  | 43773 |
| &nbsp;&nbsp;&nbsp;Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; U.S. treasuries | 78388 |  |  | 78388 |
| &nbsp;&nbsp;&nbsp;&nbsp; U.S. agency securities |  | 13248 |  | 13248 |
| &nbsp;&nbsp;&nbsp;&nbsp; Corporate bonds |  | 69032 |  | 69032 |
| &nbsp;&nbsp;&nbsp;&nbsp; Commercial paper |  | 7683 |  | 7683 |
|  | 78388 | 89963 |  | 168351 |
| &nbsp;&nbsp;&nbsp;Foreign exchange derivative contracts |  | 832 |  | 832 |
| &nbsp;&nbsp;&nbsp;Promissory note receivable |  |  | 1515 | 1515 |
| &nbsp;&nbsp;&nbsp;Interest rate swap derivative contracts |  | 1485 |  | 1485 |
| Total assets | $119627 | $94814 | $1515 | $215956 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **December 28, 2024** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| &nbsp;&nbsp;&nbsp;Assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $131519 | $— | $— | $131519 |
| &nbsp;&nbsp;&nbsp;Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; U.S. treasuries | 71252 |  |  | 71252 |
| &nbsp;&nbsp;&nbsp;&nbsp; U.S. agency securities |  | 13869 |  | 13869 |
| &nbsp;&nbsp;&nbsp;&nbsp; Corporate bonds |  | 83176 |  | 83176 |
| &nbsp;&nbsp;&nbsp;&nbsp; Commercial paper |  | 998 |  | 998 |
|  | 71252 | 98043 |  | 169295 |
| &nbsp;&nbsp;&nbsp;Promissory note receivable |  |  | 1512 | 1512 |
| &nbsp;&nbsp;&nbsp;Interest rate swap derivative contracts |  | 2025 |  | 2025 |
| Total assets | $202771 | $100068 | $1512 | $304351 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign exchange derivative contracts | $— | $(1141) | $— | $(1141) |
| Total liabilities | $— | $(1141) | $— | $(1141) |

---

***Cash Equivalents***

The fair value of our cash equivalents is determined based on quoted market prices for similar or identical securities.

***Marketable Securities***

We classify our marketable securities as available-for-sale and value them utilizing a market approach. Our investments are priced by pricing vendors who provide observable inputs for their pricing without applying significant judgment. Broker pricing is used mainly when a quoted price is not available, the investment is not priced by our pricing vendors or when a broker price is more reflective of fair value. Our broker-priced investments are categorized as Level 2 investments because fair value is based on similar assets without applying significant judgments. In addition, all investments have a sufficient trading volume to demonstrate that the fair value is appropriate.

Unrealized gains and losses were immaterial and were recorded as a component of Accumulated other comprehensive income (loss) in our Condensed Consolidated Balance Sheets. We did not have any other-than-temporary unrealized gains or losses at either period end included in these financial statements.

------

***Interest Rate Swap***

The fair value of our interest rate swap contract is determined at the end of each reporting period based on valuation models that use interest rate yield curves as inputs. For accounting purposes, our interest rate swap contract qualifies for, and is designated as a cash flow hedge. The hedged risk is the interest rate exposure to changes in interest payments attributable to changes in our variable-rate interest over the interest rate swap term. The changes in cash flows of the interest rate swap are expected to exactly offset changes in cash flows of the variable-rate debt. Cash settlements, in the form of cash payments or cash receipts, are recognized as a component of interest expense. The cash flows associated with the interest rate swaps are reported in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows and the fair value of the interest rate swap contracts are recorded within Prepaid expenses and other current assets and Other assets in our Condensed Consolidated Balance Sheets.

***Foreign Exchange Derivative Contracts***

We operate and sell our products in various global markets. As a result, we are exposed to changes in foreign currency exchange rates. We utilize foreign currency forward contracts to hedge against future movements in foreign exchange rates that affect certain existing foreign currency denominated assets and liabilities and forecasted foreign currency revenue and expense transactions. Under this program, our strategy is to have increases or decreases in our foreign currency exposures mitigated by gains or losses on the foreign currency forward contracts in order to mitigate the risks and volatility associated with foreign currency transaction gains or losses.

We do not use derivative financial instruments for speculative or trading purposes. For accounting purposes, certain of our foreign currency forward contracts are not designated as hedging instruments and, accordingly, we record the fair value of these contracts as of the end of our reporting period in our Condensed Consolidated Balance Sheets with changes in fair value recorded within Other income (expense), net in our Condensed Consolidated Statement of Income for both realized and unrealized gains and losses. Certain of our foreign currency forward contracts are designated as cash flow hedges, and, accordingly, we record the fair value of these contracts as of the end of our reporting period in our Condensed Consolidated Balance Sheets with changes in fair value recorded as a component of Accumulated other comprehensive income (loss) and reclassified into earnings in the same period in which the hedged transaction affects earnings, and in the same line item on the Condensed Consolidated Statements of Income as the impact of the hedge transaction.

The fair value of our foreign exchange derivative contracts was determined based on current foreign currency exchange rates and forward points. All of our foreign exchange derivative contracts outstanding at September 27, 2025 will mature by the first quarter of fiscal 2026.

The following table provides information about our foreign currency forward contracts outstanding as of September 27, 2025 (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| **Currency** | **Contract Position** | **Contract Amount<br>(Local Currency)** | **Contract Amount<br>(U.S. Dollars)** |
| Euro | Buy | 17867 | $20114 |
| Japanese Yen | Sell | 2809935 | 18833 |
| Korean Won | Buy | 4586415 | 3281 |
| Taiwan Dollar | Sell | 117050 | 3841 |

---

Our foreign currency contracts are classified within Level 2 of the fair value hierarchy as they are valued using pricing models that utilize observable market inputs.

***Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis***

We measure and report our non-financial assets such as Property, plant and equipment, Equity investment, Goodwill and Intangible assets at fair value on a non-recurring basis if we determine these assets to be impaired or in the period when we make a business acquisition. There were no assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 27, 2025 or September 28, 2024.

**Note 9 — Warranty**

We offer warranties on certain products and record a liability for the estimated future costs associated with warranty claims at the time revenue is recognized. The warranty liability is based upon historical experience and our estimate of the level of future costs. While we engage in product quality programs and processes, our warranty obligation is affected by product failure rates, material usage and service delivery costs. We regularly monitor product returns for warranty and maintain a reserve for the related expenses based upon our historical experience and any specifically identified failures. As we sell new products to our

------

customers, we must exercise considerable judgment in estimating the expected failure rates. This estimating process is based on historical experience of similar products, as well as various other assumptions that we believe to be reasonable under the circumstances. We provide for the estimated cost of product warranties at the time revenue is recognized as a component of Cost of revenues in our Condensed Consolidated Statement of Income.

Changes in our warranty liability were as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** |
| **Balance at beginning of year** | $3558 | $3177 |
| &nbsp;&nbsp;Accruals | 3884 | 6918 |
| &nbsp;&nbsp;Settlements | (4899) | (6485) |
| **Balance at end of period** | $2543 | $3610 |

---

**Note 10 — Property, Plant and Equipment, net**

Property, plant and equipment, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 27,<br>2025** | **December 28,<br>2024** |
| Land | $35274 | $17124 |
| Building and building improvements | 46484 | 46578 |
| Machinery and equipment | 330560 | 307201 |
| Computer equipment and software | 48676 | 47344 |
| Furniture and fixtures | 7626 | 7430 |
| Leasehold improvements | 104552 | 101374 |
| Sub-total | 573172 | 527051 |
| Less: Accumulated depreciation and amortization | (405132) | (379968) |
| Net property, plant and equipment | 168040 | 147083 |
| Construction-in-progress | 89872 | 63147 |
| Total | $257912 | $210230 |

---

**Note 11 — Stockholders' Equity and Stock-Based Compensation**

***Common Stock Repurchase Programs***

On October 30, 2023, our Board of Directors authorized a two-year program to repurchase up to $75.0 million of outstanding common stock, with the primary purpose of offsetting potential dilution from issuance of common stock under our stock-based compensation programs. During fiscal 2024 we repurchased and retired 1,309,635 shares of common stock for $53.3 million. On March 29, 2025, our Board of Directors approved an increase to the repurchase program, authorizing the repurchase of an additional $1.6 million in shares of common stock. During the first fiscal quarter of 2025, we repurchased and retired 665,000 shares of common stock for $22.1 million, utilizing the remaining shares available for repurchase under the program.

On April 24, 2025, our Board of Directors authorized a new two-year program to repurchase up to $75.0 million of outstanding common stock to offset potential dilution from issuance of common stock under our stock-based compensation programs. This share repurchase program will expire on April 24, 2027. During the nine months ended September 27, 2025, we repurchased and retired 135,000 shares of common stock for $4.1 million under this plan, and as of September 27, 2025, $70.9 million remained available for future repurchases.

Our policy related to repurchases of our common stock is to charge the excess of cost over par value to additional paid-in capital once the shares are retired. Share repurchases are subject to an excise tax enabled by the Inflation Reduction Act that is generally 1% of the fair market value of the shares repurchased at the time of the repurchase, net of the fair market value of certain new stock issuances during the same taxable year. Certain exceptions apply to the excise tax. The excise tax incurred, if applicable, is included in the cost of shares repurchased in the Condensed Consolidated Statement of Stockholders Equity. All repurchases were made in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended.

------

***Private Placement***

On January 10, 2025, Advantest America, Inc., a Delaware corporation, acquired 334,971 shares of our common stock in a private placement for $44.78 per share, representing the 5-day trailing volume-weighted average price prior to signing the related private placement agreement.

***Restricted Stock Units***

Restricted stock unit ("RSU") activity under our equity incentive plan was as follows:

---

| | | |
|:---|:---|:---|
| | **Units** | **Weighted Average Grant Date Fair Value** |
| **RSUs at December 28, 2024** | 1776743 | $39.07 |
| &nbsp;&nbsp;&nbsp;Awards granted | 1149684 | 28.68 |
| &nbsp;&nbsp;&nbsp;Awards vested | (763064) | 37.28 |
| &nbsp;&nbsp;&nbsp;Awards forfeited | (115816) | 38.58 |
| **RSUs at September 27, 2025** | 2047547 | 34.08 |

---

***Performance Restricted Stock Units***

We may grant Performance RSUs ("PRSUs") to certain executives, which vest based upon us achieving certain market performance criteria.

On August 6, 2025, we granted 163,980 PRSUs to certain senior executives for a total grant date fair value of $5.4 million which will be recognized ratably over the requisite service period. The performance criteria are based on Total Shareholder Returns ("TSR") for the period of July 1, 2025 - June 30, 2028, relative to the TSR of the companies identified as being part of the S&P Semiconductors Select Industry Index (FormFactor peer companies) as of the grant date.

Of the 204,903 PRSUs granted in 2022, 73,035 shares were forfeited during the requisite service period, resulting in 131,868 shares that were subject to the achievement of certain TSR performance criteria. We achieved 77% TSR performance, which resulted in a total of 101,433 shares vested and issued in fiscal 2025 related to the fiscal 2022 PRSU grant.

PRSUs are included as part of the RSU activity above.

***Employee Stock Purchase Plan***

Information related to activity under our Employee Stock Purchase Plan ("ESPP") was as follows:

---

| | |
|:---|:---|
| | **Nine Months Ended**<br>**September 27, 2025** |
| Shares issued | 385189 |
| Weighted average per share purchase price | $28.87 |
| Weighted average per share discount from the fair value of our common stock on the date of issuance | $(5.50) |

---

***Stock-Based Compensation***

Stock-based compensation was included in our Condensed Consolidated Statements of Income as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Cost of revenues | $1941 | $1934 | $5636 | $5794 |
| Research and development | 2525 | 2679 | 7707 | 7906 |
| Selling, general and administrative | 5050 | 4323 | 15360 | 15850 |
| Total stock-based compensation | $9516 | $8936 | $28703 | $29550 |

---

------

***Unrecognized Compensation Costs***

At September 27, 2025, the unrecognized stock-based compensation was as follows (dollars in thousands):

---

| | | |
|:---|:---|:---|
| | **Unrecognized**<br>**Expense** | **Average Expected<br>Recognition Period<br>in Years** |
| Restricted stock units | $47367 | 2.18 |
| Performance restricted stock units | 10318 | 2.09 |
| Employee stock purchase plan | 1852 | 0.35 |
| Total unrecognized stock-based compensation expense | $59537 | 2.10 |

---

**Note 12 — Net Income per Share**

The following table reconciles the shares used in calculating basic net income per share and diluted net income per share (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Weighted-average shares used in computing basic net income per share | 77387 | 77406 | 77270 | 77364 |
| Add potentially dilutive securities | 347 | 1033 | 414 | 1131 |
| Weighted-average shares used in computing diluted net income per share | 77734 | 78439 | 77684 | 78495 |
| Securities not included as they would have been antidilutive | 652 | 170 | 686 | 144 |

---

**Note 13 — Commitments and Contingencies**

***Legal Matters***

From time to time, we are subject to legal proceedings and claims in the ordinary course of business, the outcomes of which cannot be estimated with certainty. Our ability to estimate the outcomes may change in the near term and the effect of any such change could have a material adverse effect on our financial position, results of operations or cash flows.

**Note 14 — Leases**

We lease real estate space under non-cancelable operating lease agreements for commercial and industrial space, as well as for a portion of our corporate headquarters located in Livermore, California. Our leases have remaining terms of one to nine years, and some leases include options to extend up to twenty years. We also have operating leases for automobiles with remaining lease terms of one year. We did not include any of our renewal options in our lease terms for calculating our lease liability as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at this time. The weighted-average remaining lease term for our operating leases was three years as of September 27, 2025 and the weighted-average discount rate was 4.8%.

The components of lease expense were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Lease expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease expense | $2132 | $2180 | $6469 | $6360 |
| &nbsp;&nbsp;&nbsp;Short-term lease expense | 127 | 102 | 364 | 247 |
| &nbsp;&nbsp;&nbsp;Variable lease expense | 877 | 1112 | 2589 | 2974 |
|  | $3136 | $3394 | $9422 | $9581 |

---

------

Future minimum payments under our non-cancelable operating leases were as follows as of September 27, 2025 (in thousands):

---

| | |
|:---|:---|
| **Fiscal Year** | **Amount** |
| Remainder of 2025 | $2269 |
| 2026 | 7961 |
| 2027 | 7527 |
| 2028 | 4038 |
| 2029 | 311 |
| Thereafter | 1254 |
| &nbsp;&nbsp;Total minimum lease payments | 23360 |
| Less: interest | (2643) |
| &nbsp;&nbsp;Present value of net minimum lease payments | 20717 |
| Less: current portion | (7400) |
| &nbsp;&nbsp;Total long-term operating lease liabilities | $13317 |

---

**Note 15 — Revenue**

**Transaction price allocated to the remaining performance obligations:** On September 27, 2025, we had $18.9 million of remaining performance obligations, which were comprised of deferred service contracts, extended warranty contracts, and contracts with overtime revenue recognition that are not yet delivered. We expect to recognize approximately 23.4% of our remaining performance obligations as revenue in the remainder of fiscal 2025, approximately 55.6% in fiscal 2026, and approximately 21.0% in fiscal 2027 and thereafter. The foregoing excludes the value of other remaining performance obligations as they have original durations of one year or less, and also excludes information about variable consideration allocated entirely to a wholly unsatisfied performance obligation.

**Contract balances:** The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable is recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period we deliver goods or provide services or when our right to consideration is unconditional. A contract asset is recorded when we have performed under the contract but our right to consideration is conditional on something other than the passage of time. Contract assets as of September 27, 2025 and December 28, 2024 were $4.6 million and $6.9 million, respectively, and are reported on the Condensed Consolidated Balance Sheets as a component of Prepaid expenses and other current assets.

Contract liabilities include payments received and payments due in advance of performance under a contract and are satisfied as the associated revenue is recognized. Contract liabilities are reported on the Condensed Consolidated Balance Sheets at the end of each reporting period as a component of Deferred revenue and Other liabilities. Contract liabilities as of September 27, 2025 and December 28, 2024 were $23.1 million and $16.9 million, respectively. During the nine months ended September 27, 2025, we recognized $13.8 million of revenue that was included in contract liabilities as of December 28, 2024.

**Costs to obtain a contract:** We generally expense sales commissions when incurred as a component of Selling, general and administrative expense, as the amortization period is typically less than one year.

**Revenue by category:** Refer to Note 16, *Operating Segments and Enterprise-Wide Information*, for further details.

**Note 16 — Operating Segments and Enterprise-Wide Information**

We operate in two reportable segments consisting of the Probe Cards segment and the Systems segment.

Our chief operating decision maker ("CODM") is our President and Chief Executive Officer, who assesses the reportable segments' performance by using each reportable segment's net contribution to make decisions about allocating resources and assessing performance for the entire company. The CODM uses net contribution for each reportable segment predominantly in the annual budget and forecasting process, as well as consideration of budget-to-actual variances on a quarterly basis when making decisions for assessment of our performance and results of operations. Certain components of net contribution are utilized to determine executive compensation along with other measures.

------

The following table provides net contribution by reportable segment and includes a reconciliation to net income before income taxes (dollars in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** |
| Revenues | $166380 | $36296 | $— | $202676 | $172174 | $35743 | $— | $207917 |
| Cost of revenues | 98451 | 21052 | (2547) | 122050 | 99319 | 20905 | (2988) | 123212 |
| Gross profit | 67929 | 15244 | (2547) | 80626 | 72855 | 14838 | (2988) | 84705 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 40.8% | 42.0% |  | 39.8% | 42.3% | 41.5% |  | 40.7% |
| Research and development | 21785 | 4404 | 2497 | 28686 | 23259 | 5166 | 2818 | 31243 |
| Selling | 7621 | 3445 | 1552 | 12618 | 8198 | 4363 | 1443 | 14004 |
| Marketing | 1620 | 1803 | 1199 | 4622 | 1873 | 1847 | 429 | 4149 |
| Net contribution | $36903 | $5592 | $(7795) | 34700 | $39525 | $3462 | $(7678) | 35309 |
| General and administrative | General and administrative |  |  | 15731 |  |  |  | 17454 |
| Factory start-up costs | Factory start-up costs |  |  | 964 |  |  |  |  |
| Operating income | Operating income |  |  | 18005 |  |  |  | 17855 |
| Interest income, net | Interest income, net |  |  | 1976 |  |  |  | 3650 |
| Other income (expense), net | Other income (expense), net |  |  | 444 |  |  |  | (558) |
| Income before income taxes and equity investment | Income before income taxes and equity investment | Income before income taxes and equity investment | Income before income taxes and equity investment | $20425 |  |  |  | $20947 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** |
| Revenues | $465008 | $104822 | $— | $569830 | $475667 | $98449 | $— | $574116 |
| Cost of revenues | 283396 | 60792 | (7555) | 351743 | 276782 | 54928 | (8063) | 339773 |
| Gross profit | 181612 | 44030 | (7555) | 218087 | 198885 | 43521 | (8063) | 234343 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 39.1% | 42.0% |  | 38.3% | 41.8% | 44.2% |  | 40.8% |
| Research and development | 63815 | 13633 | 7831 | 85279 | 67817 | 15572 | 8045 | 91434 |
| Selling | 21368 | 10529 | 5722 | 37619 | 23771 | 12123 | 4510 | 40404 |
| Marketing | 4798 | 5426 | 3652 | 13876 | 6698 | 5331 | 3892 | 15921 |
| Net contribution | $91631 | $14442 | $(24760) | 81313 | $100599 | $10495 | $(24510) | 86584 |
| General and administrative | General and administrative |  |  | 46412 |  |  |  | 50235 |
| Factory start-up costs | Factory start-up costs |  |  | 1321 |  |  |  |  |
| Gain on sale of business | Gain on sale of business |  |  |  |  |  |  | 20581 |
| Operating income | Operating income |  |  | 33580 |  |  |  | 56930 |
| Interest income, net | Interest income, net |  |  | 7935 |  |  |  | 10221 |
| Other income (expense), net | Other income (expense), net |  |  | 1328 |  |  |  | 322 |
| Income before income taxes and equity investment | Income before income taxes and equity investment | Income before income taxes and equity investment | Income before income taxes and equity investment | $42843 |  |  |  | $67473 |

---

Corporate and Other includes unallocated expenses relating to amortization of stock-based compensation expense, intangible assets, acquisition-related costs, including charges related to fixed assets stepped up to fair value, restructuring charges, and other costs, which are not used in evaluating the results of, or in allocating resources to, our reportable segments. Acquisition-related costs include transaction costs and any costs directly related to the acquisition and integration of acquired businesses.

Net contribution represents Operating income excluding general and administrative expenses, factory start-up costs, and gains on sale of business, which are not used in evaluating the results of, or in allocating resources to, our reportable segments.

------

Certain revenue category information by reportable segment was as follows (in thousands):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Probe Cards** | **Systems** | **Total** | **Probe Cards** | **Systems** | **Total** |
| **Market:** | | | | | | |
| &nbsp;&nbsp;&nbsp;Foundry & Logic | $92933 | $— | $92933 | $107446 | $— | $107446 |
| &nbsp;&nbsp;&nbsp;DRAM | 68182 |  | 68182 | 60184 |  | 60184 |
| &nbsp;&nbsp;&nbsp;Flash | 5265 |  | 5265 | 4544 |  | 4544 |
| &nbsp;&nbsp;&nbsp;Systems |  | 36296 | 36296 |  | 35743 | 35743 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $166380 | $36296 | $202676 | $172174 | $35743 | $207917 |
| **Timing of revenue recognition:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Products transferred at a point in time | $164573 | $33649 | $198222 | $166968 | $34292 | $201260 |
| &nbsp;&nbsp;&nbsp;Products and services transferred over time | 1807 | 2647 | 4454 | 5206 | 1451 | 6657 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $166380 | $36296 | $202676 | $172174 | $35743 | $207917 |
| **Geographical region:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;South Korea | $68644 | $2158 | $70802 | $40870 | $858 | $41728 |
| &nbsp;&nbsp;&nbsp;Taiwan | 35917 | 10994 | 46911 | 42105 | 5817 | 47922 |
| &nbsp;&nbsp;&nbsp;United States | 26802 | 9573 | 36375 | 45015 | 10000 | 55015 |
| &nbsp;&nbsp;&nbsp;China | 7760 | 3905 | 11665 | 27367 | 7146 | 34513 |
| &nbsp;&nbsp;&nbsp;Japan | 8406 | 2979 | 11385 | 3734 | 4322 | 8056 |
| &nbsp;&nbsp;&nbsp;Singapore | 8697 | 1240 | 9937 | 4726 | 749 | 5475 |
| &nbsp;&nbsp;&nbsp;Europe | 2441 | 4922 | 7363 | 2149 | 5607 | 7756 |
| &nbsp;&nbsp;&nbsp;Malaysia | 5633 | 181 | 5814 | 4458 | 822 | 5280 |
| &nbsp;&nbsp;&nbsp;Rest of World | 2080 | 344 | 2424 | 1750 | 422 | 2172 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $166380 | $36296 | $202676 | $172174 | $35743 | $207917 |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Probe Cards** | **Systems** | **Total** | **Probe Cards** | **Systems** | **Total** |
| **Market:** | | | | | | |
| &nbsp;&nbsp;&nbsp;Foundry & Logic | $277718 | $— | $277718 | $297874 | $— | $297874 |
| &nbsp;&nbsp;&nbsp;DRAM | 174097 |  | 174097 | 164122 |  | 164122 |
| &nbsp;&nbsp;&nbsp;Flash | 13193 |  | 13193 | 13671 |  | 13671 |
| &nbsp;&nbsp;&nbsp;Systems |  | 104822 | 104822 |  | 98449 | 98449 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $465008 | $104822 | $569830 | $475667 | $98449 | $574116 |
| **Timing of revenue recognition:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Products transferred at a point in time | $459846 | $95227 | $555073 | $464668 | $94638 | $559306 |
| &nbsp;&nbsp;&nbsp;Products and services transferred over time | 5162 | 9595 | 14757 | 10999 | 3811 | 14810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $465008 | $104822 | $569830 | $475667 | $98449 | $574116 |
| **Geographical region:** |  |  |  |  |  |  |
| &nbsp;&nbsp;South Korea | $166689 | $4413 | $171102 | $140233 | $1319 | $141552 |
| &nbsp;&nbsp;Taiwan | 123478 | 21674 | 145152 | 109476 | 13136 | 122612 |
| &nbsp;&nbsp;United States | 87435 | 30189 | 117624 | 120046 | 28626 | 148672 |
| &nbsp;&nbsp;Japan | 20665 | 15705 | 36370 | 12594 | 11615 | 24209 |
| &nbsp;&nbsp;China | 20545 | 14135 | 34680 | 56364 | 18849 | 75213 |
| &nbsp;&nbsp;Singapore | 19057 | 3808 | 22865 | 12354 | 2401 | 14755 |
| &nbsp;&nbsp;Europe | 9200 | 13192 | 22392 | 8927 | 16493 | 25420 |
| &nbsp;&nbsp;Malaysia | 13297 | 272 | 13569 | 11150 | 2595 | 13745 |
| &nbsp;&nbsp;&nbsp;Rest of the world | 4642 | 1434 | 6076 | 4523 | 3415 | 7938 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $465008 | $104822 | $569830 | $475667 | $98449 | $574116 |

---

------

**Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations***

**Cautionary Statement Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, which are subject to known and unknown risks and uncertainties. The forward-looking statements include statements concerning, among other things, our business strategy (including the influence of anticipated trends and developments in our business and the markets in which we operate), financial and operating results, revenues, gross margins, liquidity, operating expenses, effective tax rate and deferred tax assets, products, projected costs and capital expenditure requirements, research and development programs, sales and marketing initiatives, competition and impact of accounting standards. In some cases, you can identify these statements by forward-looking words, such as "may," "might," "will," "could," "should," "expect," "estimate," "plan," "anticipate," "believe," "continue," the negative or plural of these words and other comparable terminology.

The forward-looking statements are only predictions based on our current expectations and our projections about future events. All forward-looking statements included in this Quarterly Report on Form 10-Q are based upon information available to us as of the filing date of this Quarterly Report on Form 10-Q. You should not place undue reliance on these forward-looking statements. We have no obligation to update any of these statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements, including risks related to general market trends, the benefits of acquisitions and investments, our credit facilities, our supply chain, our tax burden, uncertainties related to public health-related crises, the interpretation and impacts of changes in export controls, tariffs and other trade barriers, military conflicts, political volatility, legislative changes and similar factors, our ability to execute our business strategy including any plans of expansion, and other risks discussed in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 28, 2024 and in this Quarterly Report on Form 10-Q. You should carefully consider the numerous risks and uncertainties described under these sections.

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the accompanying notes contained in this Quarterly Report on Form 10-Q. Unless expressly stated or the context otherwise requires, the terms "we," "our," "us" and "FormFactor" refer to FormFactor, Inc. and its subsidiaries.

**Overview** 

FormFactor, Inc., headquartered in Livermore, California, is a leading provider of essential test and measurement technologies along the full semiconductor product lifecycle — from characterization, modeling, reliability, and design de-bug, to qualification and production test. We provide a broad range of high-performance probe cards, analytical probes, probe stations, thermal systems, and cryogenic systems to both semiconductor companies and scientific institutions. Our products provide electrical and optical information from a variety of semiconductor and electro-optical devices and integrated circuits from early research, through development, to high-volume production. Customers use our products and services to accelerate profitability by optimizing device performance and advancing yield knowledge.

We operate in two reportable segments consisting of the Probe Cards segment and the Systems segment. Sales of our probe cards and analytical probes are included in the Probe Cards segment, while sales of our probe stations, thermal systems and cryogenic systems are included in the Systems segment.

We generated net income of $31.1 million in the first nine months of fiscal 2025 as compared to $59.9 million in the first nine months of fiscal 2024. The decline in net income is mainly attributable to the $20.3 million gain recognized during fiscal 2024 from the sale of our China operations that also established an exclusive distribution and partnership agreement to continue sales and support of our products to that region (the "China Transaction").

In June 2025, we purchased a manufacturing site in Farmers Branch, Texas. The site, which comprises four structures and includes 50, 0000 square feet of clean room space, was purchased for $55 million dollars. This manufacturing facility enabled us to acquire a scarce, fit-for-purpose asset that aligned with our strategic roadmap and provided significant operational flexibility. Located in a lower-operating cost region, it was one of a handful of existing available facilities in the U.S. that had a clean room and came equipped with the infrastructure to meet our future manufacturing needs. We expect that the cash expenditures related to this site will be between $140.0 million and $170.0 million dollars in fiscal 2026.

------

**Critical Accounting Estimates**

Management's Discussion and Analysis and Note 2, *Summary of Significant Accounting Policies*, to the Consolidated Financial Statements in our 2024 Annual Report on Form 10-K describe the significant accounting estimates and significant accounting policies used in preparation of the Consolidated Financial Statements. Actual results in these areas could differ from management's estimates. During the nine months ended September 27, 2025, there were no significant changes in our significant accounting policies or estimates from those reported in our Annual Report on Form 10-K for the year ended December 28, 2024 except for the addition of a policy related to Equity Investments.

*Equity Investment*

On February 21, 2025, Frontier Investments Co., Ltd ("HoldCo"), a joint holding company in which we hold a 20% share of the equity and an affiliate of MBK Partners holds an 80% share of the equity, through HoldCo's wholly-owned subsidiary, FM Holdings Co., Ltd., acquired 100% of the shares of FICT Limited ("FICT") from Advantage Partners Inc. Our initial $67.2 million investment comprised of the funding of our share of the purchase price of $59.6 million, subject to changes in foreign currency fluctuations, and acquisition costs of $7.5 million. Headquartered in Nagano, Japan, FICT is a provider of semiconductor test and high-performance computing industries with complex multi-layer organic substrates, printed circuit boards, and related leading-edge technologies and services.

This investment is accounted for as an equity method investment, with the income or loss from our pro-rata share of the HoldCo's financial results changing our carrying value of the investment. We report our pro-rata share of the HoldCo's financial results on a one-quarter lag as their results are not available in time to be recorded in the concurrent period. During the three and nine months ended September 27, 2025, we recorded income of $1.2 million and a loss of $2.3 million, respectively, from our equity share of the HoldCo using lag reporting. As of September 27, 2025, the carrying value of our investment was $66.4 million, and recorded in Equity investment on our Condensed Consolidated Balance Sheets.

As of September 27, 2025, we had a $7.3 million basis difference between the carrying value of our investment and our proportionate share of the underlying net assets of the Holdco. The basis difference is accounted for as equity method goodwill that is not amortized.

**Results of Operations**

The following table sets forth our operating results as a percentage of revenues for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of revenues | 60.2 | 59.3 | 61.7 | 59.2 |
| Gross profit | 39.8 | 40.7 | 38.3 | 40.8 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | 14.1 | 15.0 | 15.0 | 15.9 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 16.3 | 17.1 | 17.2 | 18.6 |
| &nbsp;&nbsp;&nbsp;Factory start-up costs | 0.5 |  | 0.2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 30.9 | 32.1 | 32.4 | 34.5 |
| Gain on sale of business |  |  |  | 3.6 |
| Operating income | 8.9 | 8.6 | 5.9 | 9.9 |
| Interest income, net | 1.0 | 1.8 | 1.4 | 1.8 |
| Other income (expense), net | 0.2 | (0.3) | 0.2 | 0.1 |
| Income before income taxes and equity investment | 10.1 | 10.1 | 7.5 | 11.8 |
| Provision for income taxes | 2.9 | 1.1 | 1.6 | 1.4 |
| Loss (income) from equity investment | (0.5) |  | 0.4 |  |
| Net income | 7.7% | 9.0% | 5.5% | 10.4% |

---

------

***Revenues by Segment and Market***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Probe Cards | $166380 | $172174 | $465008 | $475667 |
| Systems | 36296 | 35743 | 104822 | 98449 |
|  | $202676 | $207917 | $569830 | $574116 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **% of Revenues** | **September 28,<br>2024** | **% of Revenues** | **$ Change** | **% Change** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Probe Cards Markets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foundry & Logic | $92933 | 45.9% | $107446 | 51.7% | $(14513) | (13.5)% |
| &nbsp;&nbsp;&nbsp;DRAM | 68182 | 33.6 | 60184 | 28.9 | 7998 | 13.3 |
| &nbsp;&nbsp;&nbsp;Flash | 5265 | 2.6 | 4544 | 2.2 | 721 | 15.9 |
| Systems Market: |  |  |  |  |  |  |
| &nbsp;&nbsp;Systems | 36296 | 17.9 | 35743 | 17.2 | 553 | 1.5 |
| &nbsp;&nbsp;&nbsp;Total revenues | $202676 | 100.0% | $207917 | 100.0% | $(5241) | (2.5)% |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,<br>2025** | **% of Revenues** | **September 28,<br>2024** | **% of Revenues** | **$ Change** | **% Change** |
|  | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Probe Cards Markets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foundry & Logic | $277718 | 48.7% | $297874 | 51.9% | $(20156) | (6.8)% |
| &nbsp;&nbsp;&nbsp;DRAM | 174097 | 30.6 | 164122 | 28.6 | 9975 | 6.1 |
| &nbsp;&nbsp;&nbsp;Flash | 13193 | 2.3 | 13671 | 2.4 | (478) | (3.5) |
| Systems Market: |  |  |  |  |  |  |
| &nbsp;&nbsp;Systems | 104822 | 18.4 | 98449 | 17.1 | 6373 | 6.5 |
| &nbsp;&nbsp;&nbsp;Total revenues | $569830 | 100.0% | $574116 | 100.0% | $(4286) | (0.7)% |

---

*Foundry & Logic* **—** The decrease in Foundry & Logic product revenue for the three and nine months ended September 27, 2025, compared to the three and nine months ended September 28, 2024, was driven by weaker probe-card demand for client PC and server microprocessor designs.

*DRAM* **—** The increase in DRAM product revenue for the three and nine months ended September 27, 2025, compared to the the three and nine months ended September 28, 2024, was driven by increased demand for high-bandwidth memory ("HBM") designs utilized in generative artificial intelligence applications, partially offset by lower demand for other non-HBM DRAM designs, due to volatility from trade restrictions with China.

*Flash* **—** The decrease in Flash product revenue for the nine months ended September 27, 2025, compared to the nine months ended September 28, 2024, was driven by decreased customer production activity and demand for our products. The increase in Flash product revenue for the three months ended September 27, 2025, compared to the three months ended September 28, 2024, was driven by increased customer production activity and demand for our products.

*Systems* **—** The increase in Systems market revenue for the nine months ended September 27, 2025, compared to the nine months ended September 28, 2024, was driven by increased sales of cryogenic systems, probe stations, and thermal systems. The increase in Systems market revenue for the three months ended September 27, 2025, compared to the three months ended September 28, 2024, was driven by increased sales of thermal systems and probe stations, partially offset by a decline in cryogenic systems.

------

***Revenues by Geographic Region***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **% of Revenues** | **September 28,<br>2024** | **% of Revenues** | **September 27,<br>2025** | **% of <br>Revenue** | **September 28,<br>2024** | **% of <br>Revenue** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| South Korea | $70802 | 34.9% | $41728 | 20.1% | $171102 | 30.0% | $141552 | 24.7% |
| Taiwan | 46911 | 23.1 | 47922 | 23.0 | 145152 | 25.5 | 122612 | 21.4 |
| United States | 36375 | 17.9 | 55015 | 26.5 | 117624 | 20.6 | 148672 | 25.9 |
| China | 11665 | 5.8 | 34513 | 16.6 | 34680 | 6.1 | 75213 | 13.1 |
| Japan | 11385 | 5.6 | 8056 | 3.9 | 36370 | 6.4 | 24209 | 4.2 |
| Singapore | 9937 | 4.9 | 5475 | 2.6 | 22865 | 4.0 | 14755 | 2.6 |
| Europe | 7363 | 3.6 | 7756 | 3.7 | 22392 | 3.9 | 25420 | 4.4 |
| Malaysia | 5814 | 2.9 | 5280 | 2.5 | 13569 | 2.4 | 13745 | 2.4 |
| Rest of the world | 2424 | 1.3 | 2172 | 1.1 | 6076 | 1.1 | 7938 | 1.3 |
| &nbsp;&nbsp;&nbsp;Total revenues | $202676 | 100.0% | $207917 | 100.0% | $569830 | 100.0% | $574116 | 100.0% |

---

Geographic revenue information is based on the location to which we ship the product. For example, if a certain South Korean customer purchases through its U.S. subsidiary and requests the products to be shipped to an address in South Korea, this sale will be reflected in the revenue for South Korea rather than the U.S.

Changes in revenue by geographic region for the three and nine months ended September 27, 2025, compared to the three and nine months ended September 28, 2024, were primarily attributable to changes in customer demand, impacts from trade restrictions, and product sales mix.

***Cost of Revenues and Gross Margins***

Cost of revenues consists primarily of manufacturing materials, compensation and benefits, shipping and handling costs, manufacturing-related overhead (including equipment costs, related occupancy, and computer services), warranty costs, inventory adjustments (including write-downs for inventory obsolescence), and amortization of certain intangible assets. Our manufacturing operations rely on a limited number of suppliers to provide key components and materials for our products, some of which are a sole source. We order materials and supplies based on backlog and forecasted customer orders. Tooling and setup costs related to changing manufacturing lots at our suppliers are also included in the cost of revenues. We expense all warranty costs, inventory provisions and amortization of certain intangible assets as cost of revenues.

Our gross profit and gross margin were as follows (dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
| Gross profit | $80626 | $84705 | $(4079) | (4.8)% |
| Gross margin | 39.8% | 40.7% |  |  |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
| Gross profit | $218087 | $234343 | $(16256) | (6.9)% |
| Gross margin | 38.3% | 40.8% |  |  |

---

------

Our gross profit and gross margin by segment were as follows (dollars in thousands):

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
| | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** |
| Gross profit | $67929 | $15244 | $(2547) | $80626 | $72855 | $14838 | $(2988) | $84705 |
| Gross margin | 40.8% | 42.0% |  | 39.8% | 42.3% | 41.5% |  | 40.7% |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** | **September 28, 2024** |
|  | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** | **Probe Cards** | **Systems** | **Corporate and Other** | **Total** |
| Gross profit | $181612 | $44030 | $(7555) | $218087 | $198885 | $43521 | $(8063) | $234343 |
| Gross margin | 39.1% | 42.0% |  | 38.3% | 41.8% | 44.2% |  | 40.8% |

---

*Probe Cards* **—** For the three and nine months ended September 27, 2025, gross profit and gross margins decreased compared to the three and nine months months ended September 28, 2024, primarily due to higher manufacturing costs, which included increased costs for tariffs, partially offset by a favorable product mix.

*Systems* **—** For the three months ended September 27, 2025, gross profit increased on greater revenue with gross margins increasing slightly, benefitting from the increase in volume when compared to the three months ended September 28, 2024. For the nine months ended September 27, 2025, gross profit increased while gross margins decreased compared to the nine months ended September 28, 2024, primarily as a result of greater revenues that was offset by an unfavorable product mix as a greater percentage of segment revenues were from lower margin products.

*Corporate and Other* **—** Corporate and Other includes unallocated expenses relating to stock-based compensation expense, amortization of intangible assets and fixed asset fair value adjustments due to acquisitions, and restructuring charges, net, which are not used in evaluating the results of, or in allocating resources to, our reportable segments.

*Overall* **—** Gross profit and gross margins fluctuate with revenue levels, product mix, selling prices, factory loading, and material costs. For the three months ended September 27, 2025, compared to the three months ended September 28, 2024, gross profit and gross margins decreased due to higher manufacturing costs, which included increased costs for tariffs, partially offset by a favorable product mix as described above. For the nine months ended September 27, 2025, compared to the nine months ended September 28, 2024, gross profit and gross margins decreased due to higher manufacturing costs, which included increased costs for tariffs.

Cost of revenues included stock-based compensation expense as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Stock-based compensation | $1941 | $1934 | $5636 | $5794 |

---

***Research and Development***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Research and development | $28686 | $31243 | $(2557) | (8.2)% |
| % of revenues | 14.1% | 15.0% |  |  |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
|  | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Research and development | $85279 | $91434 | $(6155) | (6.7)% |
| % of revenues | 15.0% | 15.9% |  |  |

---

------

Research and development expenses in the three and nine months ended September 27, 2025 decreased compared to the corresponding periods in the prior year primarily due to lower general operational costs, which includes the benefit of a German government grant earned that partially offset expenses, lower project material costs, and lower employee compensation costs from lower performance-based compensation that was partially offset by an increase in employee compensation costs from an increase in headcount and annual pay increases.

A detail of the changes is as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended September 27, 2025 compared to Three Months Ended September 28, 2024** | **Nine Months Ended September 27, 2025 compared to Nine Months Ended September 28, 2024** |
| General operational costs | $(1634) | $(2085) |
| Project material costs | (409) | (1342) |
| Employee compensation costs | (360) | (2529) |
| Stock-based compensation expense | (154) | (199) |
|  | $(2557) | $(6155) |

---

Research and development included stock-based compensation expense as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Stock-based compensation expense | $2525 | $2679 | $7707 | $7906 |

---

***Selling, General and Administrative***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Selling, general and administrative | $32971 | $35607 | $(2636) | (7.4)% |
| % of revenues | 16.3% | 17.1% |  |  |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
|  | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Selling, general and administrative | $97907 | $106560 | $(8653) | (8.1)% |
| % of revenues | 17.2% | 18.6% |  |  |

---

Selling, general and administrative expenses decreased for the three and nine months ended September 27, 2025 compared to the corresponding period in the prior year. The decrease for the three and nine month periods was primarily due to decreased employee compensation costs from lower performance-based compensation that was partially offset by an increase in employee costs from annual pay increases. The decrease for the three month period was further driven by lower commission expenses and consulting fees that were partially offset by increased stock-based compensation expense. The decrease for the nine month period was further driven by lower consulting fees, general operating expenses, commission expenses, and stock-based compensation expense, partially offset by increased restructuring charges from operating efficiency initiatives.

------

A detail of the changes is as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended September 27, 2025 compared to Three Months Ended September 28, 2024** | **Nine Months Ended September 27, 2025 compared to Nine Months Ended September 28, 2024** |
| Employee compensation costs | $(1467) | $(5737) |
| Commission expenses | (771) | (671) |
| Stock-based compensation expense | 727 | (490) |
| Consulting fees | (478) | (1909) |
| General operating expenses | (647) | (2853) |
| Restructuring charges |  | 3007 |
|  | $(2636) | $(8653) |

---

Selling, general and administrative included stock-based compensation expense as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| Stock-based compensation expense | $5050 | $4323 | $15360 | $15850 |

---

***Factory Start-Up Costs***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Factory start-up costs | $964 | $— | $964 |  |
| % of revenues | 0.5% | —% |  |  |
|  | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 27,<br>2025** | **September 28,<br>2024** | **$ Change** | **% Change** |
|  | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Factory start-up costs | $1321 | $— | $1321 |  |
| % of revenues | 0.2% | —% |  |  |

---

Factory start-up costs are current year costs associated with our newly purchased manufacturing site in Farmers Branch, Texas. The start-up costs consist of utilities, employee compensation costs, taxes and licenses, facility maintenance, and other expenses being incurred while the site is being brought to its intended use. These costs are expected to increase as we continue the build-out, with an expected production ramp beginning late in the fourth quarter of fiscal 2026.

------

***Interest Income, Net***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| Interest Income | $2126 | $3770 | $8276 | $10542 |
| Weighted average balance of cash and investments | $254119 | $363178 | $297737 | $349157 |
| Weighted average yield on cash and investments | 3.93% | 4.68% | 4.22% | 4.59% |
| Interest Expense | $150 | $120 | $341 | $321 |
| Average debt outstanding | $12550 | $13651 | $12829 | $13920 |
| Weighted average interest rate on debt | 2.75% | 2.75% | 2.75% | 2.75% |

---

Interest income is earned on our cash, cash equivalents, restricted cash and marketable securities. The decrease in interest income for the three and nine months ended September 27, 2025, compared with the corresponding periods in the prior year, was attributable to lower invested balances and lower yields.

Interest expense primarily includes interest on our term loan, interest rate swap derivative contracts, commitment fee on our revolving credit facility, term loan issuance costs amortization charges, and our revolving credit facility issuance costs amortization charges. The interest expense for the three and nine months ended September 27, 2025 increased due to entering into the revolving credit facility within the quarter.

***Other Income (Expense), Net***

Other income (expense), net, primarily includes the effects of foreign currency and various other gains and losses. We partially mitigate our risks from currency movements by hedging certain balance sheet exposures, which minimizes the impacts during periods of foreign exchange volatility.

***Provision for Income Taxes***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** | **September 27,<br>2025** | **September 28,<br>2024** |
| | **(In thousands, except percentages)** | **(In thousands, except percentages)** | **(In thousands, except percentages)** | **(In thousands, except percentages)** |
| Provision for income taxes | $5937 | $2211 | $9384 | $7564 |
| Effective tax rate | 29.1% | 10.6% | 21.9% | 11.2% |

---

Provision for income taxes reflects the tax provision on our operations in foreign and U.S. jurisdictions, offset by tax benefits from tax credits and the foreign-derived intangible income deduction. Our effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to U.S. federal, state or foreign tax laws, changes in stock-based compensation expense/benefit, future expansion into areas with varying country, state, and local income tax rates, and deductibility of certain costs and expenses by jurisdiction. The increase in our effective tax rate for the three and nine months ended September 27, 2025 compared to the corresponding periods in the prior year was primarily driven by changes in the estimated taxable income by jurisdiction and the impact of implementing the One Big Beautiful Bill Act ("OBBBA") tax law changes. Although the impacts of OBBBA applied for the current fiscal year, the changes were adopted within the three months ended September 27, 2025. The increase in our effective tax rate for the three months ended September 27, 2025 compared to the corresponding period in the prior year was further impacted by discrete stock-based compensation impacts in the prior year on the provision for income tax expense, that did not repeat in the current year.

*One Big Beautiful Bill*

On July 4, 2025, the OBBBA, which included a broad range of tax reform provisions that affected our financial results, was signed into law in the United States. Among other provisions, the OBBBA repealed the capitalization of domestic Research and Development ("R&D") expenditures and included a reduced deduction rate on Foreign-derived Deduction Eligible Income and income from non-U.S. subsidiaries. We evaluated the impact of these provisions and implemented our current strategy that optimizes our overall effective tax rate. We will continue to evaluate the full impact of these legislative changes as more guidance becomes available.

------

**Liquidity and Capital Resources**

***Capital Resources***

Our working capital decreased to $429.1 million at September 27, 2025, compared to $473.8 million at December 28, 2024.

Cash and cash equivalents primarily consist of deposits held at banks and money market funds. Marketable securities primarily consist of corporate bonds, U.S. treasuries, U.S. agency securities, and commercial paper. We typically invest in highly rated securities with low probabilities of default. Our investment policy requires investments to be rated single A or better, and limits the types of acceptable investments, issuer concentration and duration of the investment.

Our cash, cash equivalents and marketable securities totaled approximately $266.0 million at September 27, 2025, compared to $360.0 million at December 28, 2024. We have the full amount available under our $150 million revolving credit facility as of September 27, 2025. Based on our historical results of operations, we expect that our cash, cash equivalents, and marketable securities on hand, the cash we expect to generate from operations, and the available capacity under our revolving credit facility, will be sufficient to fund our short-term and long-term liquidity requirements primarily arising from: research and development, capital expenditures, working capital, outstanding commitments, and other liquidity requirements associated with existing operations. However, we cannot be certain that our cash, cash equivalents, and marketable securities on hand, and cash generated from operations, will be available in the future to fund all of our capital and operating requirements. In addition, any future strategic investments and significant acquisitions may require additional cash and capital resources. To the extent necessary, we may consider entering into short and long-term debt obligations, raising cash through a stock issuance, or obtaining new financing facilities, which may not be available on terms favorable to us. If we are unable to obtain sufficient cash or capital to meet our needs on a timely basis and on favorable terms, our business and operations could be materially and adversely affected.

If we are unsuccessful in maintaining or growing our revenues, maintaining or reducing our cost structure, or increasing our available cash through debt or equity financings, our cash, cash equivalents and marketable securities may decline.

We utilize a variety of tax planning and financing strategies to manage our worldwide cash and deploy funds to locations where needed. As part of these strategies, we indefinitely reinvest a portion of our foreign earnings. Should we require additional capital in the United States, we may elect to repatriate indefinitely-reinvested foreign funds or raise capital in the United States.

***Cash Flows***

The following table sets forth our net cash flows from operating, investing and financing activities:

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended** | **Nine Months Ended** |
| | **September 27,<br>2025** | **September 28,<br>2024** |
| | **(In thousands)** | **(In thousands)** |
| Net cash provided by operating activities | $69423 | $81621 |
| Net cash used in investing activities | $(156495) | $(26152) |
| Net cash used in financing activities | $(9560) | $(46256) |

---

***Operating Activities***

Net cash provided by operating activities consists of net income for the period, adjusted for certain non-cash items and changes in certain operating assets and liabilities. Net cash provided by operating activities for the nine months ended September 27, 2025 was attributable to net income of $31.1 million and net non-cash expenses of $79.4 million, partially offset by the increase in net working capital of $41.1 million. The cash used in net working capital was primarily driven by increased accounts receivable, net, of $28.1 million, increased inventories of $13.9 million, decreased operating lease liabilities of $6.1 million, and increased prepaid expenses and other current assets of $4.5 million, partially offset by increased deferred revenue of $6.2 million and accounts payable of $5.7 million. The non-cash expenses mainly consisted of depreciation, amortization, stock-based compensation, and the provision for excess and obsolete inventories.

***Investing Activities***

Net cash used in investing activities for the nine months ended September 27, 2025 primarily related to $92.3 million of property, plant and equipment purchases, with $55.0 million of the property, plant and equipment purchases relating to our new Farmers Branch manufacturing facility in Texas, and $67.2 million used to acquire our equity investment in FICT, partially offset by $2.9 million in net proceeds from the maturities and sale of marketable securities.

------

***Financing Activities***

Net cash used in financing activities for the nine months ended September 27, 2025 primarily related to $26.2 million used to purchase common stock under our stock repurchase program, $8.6 million used to pay tax withholdings for net share settlements of employee stock awards, partially offset by $26.1 million received from issuances of common stock through a private placement of $15.0 million and under our employee stock purchase plan of $11.1 million.

**Debt**

***Revolving Credit Agreement***

On July 29, 2025, we entered into a Revolving Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as Administrative Agent, and the lenders party thereto, providing us with a $150 million revolving credit facility (the "Facility"). The Facility has a maturity date of July 29, 2030. The Facility may be used for working capital and other general corporate purposes, subject to the terms and conditions set forth in the Credit Agreement. No amounts were outstanding under the Facility as of September 27, 2025.

Borrowings under the Facility will bear interest at a fluctuating rate per annum equal to, at our option, (i) the forward-looking secured overnight financing rate ("SOFR") term, (ii) a base rate set forth in the Credit Agreement, or (iii) a combination thereof, plus, in each case, an applicable margin calculated based on our leverage ratio. Voluntary prepayments are permissible without penalty, subject to certain conditions pertaining to minimum notice and minimum prepayment and reduction amounts as described in the Credit Agreement.

The Facility also bears a quarterly commitment fee ranging from 0.15% to 0.25% on the daily amount by which the commitments under the Facility exceed the outstanding amount. The commitment fee as of September 27, 2025 was 0.15%.

The Credit Agreement contains customary representations and warranties, and affirmative and negative covenants and events of default, including limitations on subsidiary indebtedness and liens, and the requirement to maintain specified financial ratios including the requirement to maintain a consolidated total net leverage ratio not exceeding 3.50 to 1.00 as of the last day of each fiscal quarter with an increase to 4.00 to 1.00 for four quarters following a permitted acquisition. We were in compliance with the Facility's covenants as of September 27, 2025.

***Building Term Loan and Interest Rate Swap***

On June 22, 2020, we entered into an $18.0 million 15-year credit facility loan agreement (the "Building Term Loan"). The proceeds of the Building Term Loan were used to purchase a building adjacent to our leased facilities in Livermore, California. On May 19, 2023, we amended the Building Term Loan, replacing the benchmark reference rate London Interbank Offered Rate ("LIBOR") with the term SOFR, with no change to the amount or timing of contractual cash flows.

The Building Term Loan bears interest at a rate equal to the applicable SOFR rate plus 1.86% per annum. Interest payments are payable in monthly installments over a fifteen-year period. The interest rate at September 27, 2025, before consideration of interest rate swap discussed in the next paragraph, was 6.14%. As of September 27, 2025, the balance outstanding pursuant to the Building Term Loan was $12.5 million.

On March 17, 2020, we entered into an interest rate swap agreement to hedge the interest payment on the Building Term Loan for the notional amount of $18.0 million, and an amortization period that matches the debt. As future levels of LIBOR over the life of the loan were uncertain, we entered into this interest-rate swap agreement to hedge the exposure in interest rate risks associated with movement in LIBOR rates. This agreement was amended on May 19, 2023 to replace the benchmark reference rate LIBOR with SOFR to match the Building Term Loan agreement (as amended). After the amendment, the interest rate swap continues to convert our floating-rate interest into a fixed-rate at 2.75%. As of September 27, 2025, the notional amount of the loan that is subject to this interest rate swap is $12.5 million.

**Stock Repurchase Programs**

On October 30, 2023, our Board of Directors authorized a two-year program to repurchase up to $75.0 million of outstanding common stock, with the primary purpose of offsetting potential dilution from issuance of common stock under our stock-based compensation programs. During fiscal 2024 we repurchased and retired 1,309,635 shares of common stock for $53.3 million. On March 29, 2025, our Board of Directors approved an increase to the repurchase program, authorizing the repurchase of an additional $1.6 million in shares of common stock. During the first fiscal quarter of 2025, we repurchased and retired 665,000 shares of common stock for $22.1 million, utilizing the remaining shares available for repurchase under the program.

------

On April 24, 2025, our Board of Directors authorized a new two-year program to repurchase up to $75.0 million of outstanding common stock to offset potential dilution from issuance of common stock under our stock-based compensation programs. This share repurchase program will expire on April 24, 2027. During the nine months ended September 27, 2025, we repurchased and retired 135,000 shares of common stock for $4.1 million under this plan, and as of September 27, 2025, $70.9 million remained available for future repurchases.

**Contractual Obligations and Commitments**

The following table summarizes our significant contractual commitments to make future payments in cash under contractual obligations as of September 27, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** | **Payments Due In Fiscal Year** |
| | **Remainder**<br> **2025** | **2026** | **2027** | **2028** | **2029** | **Thereafter** | **Total** |
| Operating leases | $2269 | $7961 | $7527 | $4038 | $311 | $1254 | $23360 |
| Term loans - principal payments | 281 | 1142 | 1175 | 1208 | 1242 | 7490 | 12538 |
| Term loans - interest payments <sup>(1)</sup> | 394 | 736 | 664 | 591 | 515 | 1344 | 4244 |
| Revolver - commitment fee<sup>(2)</sup> | 56 | 224 | 224 | 229 | 224 | 129 | 1086 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $3000 | $10063 | $9590 | $6066 | $2292 | $10217 | $41228 |

---

<sup>(1)</sup> Represents our minimum interest payment commitments at 6.14% per annum, excluding the interest rate swap described in *Debt*, above.

<sup>(2)</sup> Represents our quarterly commitment fee of 0.15% on the daily amount by which the commitments under the Facility exceed the outstanding amount. This commitment assumes no borrowings.

The table above excludes our gross liability for unrecognized tax benefits and our deferred grant. The gross liability for unrecognized tax benefits was $52.0 million as of September 27, 2025. The timing of any payments which could result from these unrecognized tax benefits will depend upon a number of factors and, accordingly, the timing of payment cannot be estimated. The deferred grant was $18.0 million as of September 27, 2025, and consists of cash received from a California Competes Grant awarded from the California Governor's Office of Business and Economic Development. The timing of any potential repayments is dependent upon a number of factors, including the number of employees and capital investments within California over the 5-year term. Accordingly, the timing of any repayment cannot be estimated.

**Off-Balance Sheet Arrangements**

Historically, we have not participated in transactions that have generated relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of September 27, 2025, we were not involved in any such off-balance sheet arrangements.

**Recent Accounting Standards**

For a description of a recent change in accounting standards, including the expected dates of adoption and estimated effects, if any, in our condensed consolidated financial statements, see Note 1, *Basis of Presentation and Significant Accounting Policies,* in Part I, Item 1 of this Form 10-Q.

**Item 3. *Quantitative and Qualitative Disclosures about Market Risk***

For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to Item 7A "Quantitative and Qualitative Disclosures about Market Risk" contained in Part II of our Annual Report on Form 10-K for the fiscal year ended December 28, 2024. Our exposure to market risk has not changed materially since December 28, 2024.

------

**Item 4. *Controls and Procedures***

**Evaluation of Disclosure Controls and Procedures**

Based on our management's evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the "Exchange Act")) are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Limitations on the Effectiveness of Controls**

Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems' objectives are being met. Further, the design of any control systems must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based, in part, on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

**CEO and CFO Certifications**

We have attached as exhibits to this Quarterly Report on Form 10-Q the certifications of our Chief Executive Officer and Chief Financial Officer, which are required in accordance with the Exchange Act. We recommend that this Item 4 be read in conjunction with the certifications for a more complete understanding of the subject matter presented.

**PART II - OTHER INFORMATION**

**Item 1A. *Risk Factors***

There have been no material changes during the three months ended September 27, 2025 to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 28, 2024 and in our Quarterly Reports on Form 10-Q for the quarters ended March 29, 2025 and June 28, 2025. If any of the identified risks actually occur, our business, financial condition and results of operations could suffer. The trading price of our common stock could decline and you may lose all or part of your investment in our common stock. The risks and uncertainties described in our Annual Report on Form 10-K for the year ended December 28, 2024 and in our Quarterly Reports on Form 10-Q for the quarters ended March 29, 2025 and June 28, 2025 are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business operations.

------

**Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

**Repurchase of Common Stock**

The following table summarizes our repurchases of outstanding common stock for the three months ended September 27, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period (fiscal months)** | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs** | **Maximum Amount that May Yet Be Purchased Under the Plans or Programs**<sup>(1)(2)</sup> |
| &nbsp;&nbsp;June 29, 2025 - July 26, 2025 |  | $— |  | $72588038 |
| &nbsp;&nbsp;July 27, 2025 - August 23, 2025 | 60000 | 27.63 | 60000 | 70930064 |
| &nbsp;&nbsp;August 24, 2025 - September 27, 2025 |  |  |  | 70930064 |
|  | 60000 | $27.63 | 60000 |  |

---

<sup>1</sup> In April 2025, our Board of Directors authorized a program to repurchase up to $75.0 million of outstanding common stock to offset potential dilution from issuances of our common stock under our employee stock purchase plan and equity incentive plan. Under the authorized stock repurchase program, we may repurchase shares from time to time on the open market. The pace of repurchase activity will depend on levels of cash generation, current stock price and other factors. The program may be modified or discontinued at any time. This share repurchase program will expire April 2027.

<sup>2</sup> Amounts exclude the 1% surcharge on stock repurchases under the Inflation Reduction Act's excise tax. This excise tax, if applicable, is recorded in equity and excluded from the amount available under the repurchase program.

**Item 5. *Other Information***

**Rule 10b5-1 Trading Arrangements**

During the quarter ended September 27, 2025, no director or officer of the Company adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-K, except as follows:

On July 31, 2025, Dr. Mike Slessor, the Company's Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement for the potential sale of up to 84,002 shares of our common stock. This arrangement was initially adopted on November 20, 2023.

On August 19, 2025, Dr. Mike Slessor, the Company's Chief Executive Officer, adopted a Rule 10b5-1 trading agreement. Under this arrangement, a total of up to 169,624 shares of our common stock may be sold, subject to certain conditions, after November 19, 2025 and before the arrangement expires on November 19, 2027.

The above arrangements are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.

------

**Item 6. *Exhibits***

The following exhibits are filed herewith and this list constitutes the exhibit index.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit**<br>**Number** |<br>**Exhibit Description** | **Form** | **Date** | **Number** | **Filed**<br>**Herewith** |
| <u>[3.1](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000023/ex032-restatedcertificateo.htm)</u> | <u>[Restated Certificate of Incorporation of FormFactor, Inc.](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000023/ex032-restatedcertificateo.htm)</u> | 10-K | 2/21/2025 | 000-50307 |  |
| <u>[3.2](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000077/ex32-amendedandrestatedbyl.htm)</u> | <u>[Amended and Restated By-laws of FormFactor, Inc.](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000077/ex32-amendedandrestatedbyl.htm)</u> | 8-K | 7/30/2025 | 000-50307 |  |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000077/ex101-creditagreementxform.htm)</u> | <u>[Credit Agreement, dated as of July 29, 2025, by and among FormFactor, Inc. and Wells Fargo Bank, National Association, as Administrative Agent, and the lenders party thereto from time to time](https://www.sec.gov/Archives/edgar/data/1039399/000103939925000077/ex101-creditagreementxform.htm)</u> | 8-K | 7/30/2025 | 000-50307 |  |
| <u>[31.01](ex3101-ceocertxq325.htm)</u> | <u>[Certification of Chief Executive Officer pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex3101-ceocertxq325.htm)</u> |  |  |  | X |
| <u>[31.02](ex3102-cfocertxq325.htm)</u> | <u>[Certification of Chief Financial Officer pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex3102-cfocertxq325.htm)</u> |  |  |  | X |
| <u>[32.01](ex3201-soxcertxq325.htm)</u> | <u>[Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex3201-soxcertxq325.htm)</u> |  |  |  | \* |
| 101 | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended September 27, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Stockholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags |  |  |  | X |
| 101.INS | XBRL Instance Document |  |  |  | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document |  |  |  | X |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |  |  |  | X |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |  |  |  | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  | X |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 27, 2025, formatted in Inline XBRL (included as Exhibit 101) |  |  |  | X |

---

______________________________________

\*&nbsp;&nbsp;&nbsp;&nbsp;This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | FormFactor, Inc. | FormFactor, Inc. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: | November 4, 2025 | By: | /s/ ARIC MCKINNIS |
|  |  |  | Aric McKinnis |
|  |  |  | Chief Financial Officer |
|  |  |  | *(Duly Authorized Officer, Principal Financial Officer, and Principal Accounting Officer)* |

---

## Exhibit 31.01

**EXHIBIT 31.01**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 15 U.S.C. SECTION 7241, AS**

**ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Michael D. Slessor, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed the quarterly report on Form 10-Q of FormFactor, Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | November 4, 2025 | /s/ MICHAEL D. SLESSOR |
| | | Michael D. Slessor<br>*Chief Executive Officer*<br>*(Principal Executive Officer and Director)* |

---

## Exhibit 31.02

**EXHIBIT 31.02**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 15 U.S.C. SECTION 7241, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Aric McKinnis, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed the quarterly report on Form 10-Q of FormFactor, Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | November 4, 2025 | /s/ ARIC MCKINNIS |
| | | Aric McKinnis<br>*Chief Financial Officer*<br>*(Principal Financial Officer and Principal Accounting Officer)* |

---

## Exhibit 32.01

**EXHIBIT 32.01** 

**CERTIFICATION OF**

**CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of FormFactor, Inc., a Delaware corporation, for the period ended September 27, 2025, as filed with the Securities and Exchange Commission, each of the undersigned officers of FormFactor, Inc. certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his respective knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;the quarterly report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of FormFactor, Inc. for the periods presented therein.

---

| | | |
|:---|:---|:---|
| Date: | November 4, 2025 | /s/ MICHAEL D. SLESSOR |
|  |  | Michael D. Slessor<br>*Chief Executive Officer*<br>*(Principal Executive Officer and Director)* |
| Date: | November 4, 2025 | /s/ ARIC MCKINNIS |
|  |  | Aric McKinnis<br>*Chief Financial Officer*<br>*(Principal Financial Officer and Principal Accounting Officer)* |

---

<br>